FCS Resources | TRYNGOLZA® (olezarsen)

Downloadable Resources

FCS Patient Identification Brochure

Key clinical features and tearaway diagnostic scoring tools you can use to facilitate a diagnosis of FCS.

Download PDF

TRYNGOLZA Start Form

Use this form to prescribe TRYNGOLZA for your patients and enroll them in Ionis Every Step™.

Download PDF

FCS Sample Letter of Medical Necessity

A letter template stating why TRYNGOLZA is medically necessary for your patient.

Download PDF

FCS Sample Letter of Appeal

A letter template requesting that the insurance plan overturn a coverage denial for TRYNGOLZA.

Download PDF

PreventionGenetics Brochure

An overview of FCS patient identification, diagnostic scoring tools, and no-cost genetic testing.

Download PDF

Next Learn about dosing and administration

Important safety information & Indications

IMPORTANT SAFETY INFORMATION & INDICATIONS

CONTRAINDICATIONS

TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills, and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur.

Liver Enzyme Abnormalities 

TRYNGOLZA can cause increases in liver enzymes and hepatic fat in adults. Increases in liver enzymes were more frequently reported with the 80 mg dose as compared with the 50 mg dose. Consider liver enzyme testing before TRYNGOLZA initiation or an increase in dosage and when clinically indicated thereafter. If persistent elevations in liver enzymes occur, consider dose interruption and/or dose reduction. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue TRYNGOLZA.

ADVERSE REACTIONS

Adverse Reactions for FCS
Most common adverse reactions in patients with FCS (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count, and arthralgia.

Adverse Reactions for sHTG 
Most common adverse reactions in patients with sHTG (incidence ≥2% higher than placebo) were injection site reactions and liver enzyme increases.

INDICATIONS

Familial Chylomicronemia Syndrome (FCS) 
TRYNGOLZA (olezarsen) is indicated as an adjunct to diet to reduce triglycerides (TG) in adults with familial chylomicronemia syndrome (FCS).

Severe Hypertriglyceridemia (sHTG) 
TRYNGOLZA is indicated as an adjunct to diet to reduce TG and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: TG ≥500 mg/dL).

Please see full Prescribing Information for TRYNGOLZA.

IMPORTANT SAFETY INFORMATION & INDICATIONS

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Liver Enzyme Abnormalities

ADVERSE REACTIONS

Adverse Reactions for FCS
Most common adverse reactions in patients with FCS (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count, and arthralgia.

Adverse Reactions for sHTG
Most common adverse reactions in patients with sHTG (incidence ≥2% higher than placebo) were injection site reactions and liver enzyme increases.

INDICATIONS

Familial Chylomicronemia Syndrome (FCS)
TRYNGOLZA (olezarsen) is indicated as an adjunct to diet to reduce triglycerides (TG) in adults with familial chylomicronemia syndrome (FCS).

Severe Hypertriglyceridemia (sHTG)
TRYNGOLZA is indicated as an adjunct to diet to reduce TG and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: TG ≥500 mg/dL).

Please see full Prescribing Information for TRYNGOLZA.

References: 1. TRYNGOLZA. Prescribing information. Ionis Pharmaceuticals. 2. Marston NA, Bergmark BA, Alexander VJ, et al. Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk. N Engl J Med. 2026;394(5):429-441. 3. Data on file. REF-01291. Ionis Pharmaceuticals; 2024.

FCS | Resources

FCS Patient Identification Brochure

TRYNGOLZA Start Form

FCS Sample Letter of Medical Necessity

FCS Sample Letter of Appeal

PreventionGenetics Brochure

IMPORTANT SAFETY INFORMATION & INDICATIONS

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Liver Enzyme Abnormalities

ADVERSE REACTIONS

INDICATIONS

Please see full Prescribing Information for TRYNGOLZA.